| Outcome Measures: |
Primary: Effect of nicotinamide on hepatic fibrosis, Measurement of hepatic fibrosis by Fibroscan, to asses the arrest or improvement of fibrosis (lower value than basal Fibroscan result), Fibroscan at 0 and 12 months. | Secondary: Effect of nicotinamide on body fat and hepatic fat distribution, Analysis of body and hepatic fat by magnetic ressonance and observe visual differences between the basal and final images, 0 and 12 months|Effect of nicotinamide on the general health state (weight), Analysis of body weight (grams) and waist circumference (cm), a reduction in both would point to a better general status and a weight loss, Blood test and strength test at 0, 3, 6, and 12 months|Effect of nicotinamide on the general health state (strenght), Evaluation of the grip strength as a measure of muscle strength, Blood test and strength test at 0, 3, 6, and 12 months|Effect of nicotinamide on the Insulin resistance, Calcutaltion of the HOMA-IR (homeostatic model assessment - Insulin Resistance) index, a reduction of the HOMA-IR index shows a reduction of insulin resistance and an improved glucose metabolism, Blood test and strength test at 0, 3, 6, and 12 months|Effect of nicotinamide on gut microbiota, Analyses of the gut microbiota composition during the NAM treatment, Test at 0, 3, 6, and 12 months|Effect of nicotinamide on systemic inflammation, Analysis of the evolution of systemic inflammation by ELISA (enzyme-linked immunosorbent assay) of several cytokines related to inflammation. Lower values are usually associated to lower inflammation., Blood test at 0, 3, 6, and 12 months|Effect of nicotinamide on cellular inflammation, Analysis of the evolution of cellular inflammation by analyzing the count and type of peripheral blood mononuclear cells by flow-cytometry, Blood test at 0, 3, 6, and 12 months|Security evaluation LIVER, Security evaluation of the dosage of nicotinamide administered by analyzing liver parameters of aspartate transaminase (AST), alanine transaminase (ALT), and coagulation parameters., 0, 1, 3, 6, 9, and 12 months|Security evaluation KIDNEY, Security evaluation of the dosage of nicotinamide administered by measuring glomerular filtrate and creatinine, 0, 1, 3, 6, 9, and 12 months|Effect of nicotinamide on liver parameters, Evaluation of the effects of nicotinamide on liver status by ELF-test, to observe if there is any improvement (lower value than basal measurement), 0 and 12 months
|
